ADMA BIOLOGICS, INC. (ADMA)
Biological Products, (No Diagnostic Substances)
Latest Price
$8.46
TTM P/E
12.44
Normalized P/E
42.75
Div Yield
--
Book Value
1.65
P/B Ratio
5.12
Valuation metrics
adjust assumptions →EPS: $0.60
Book value / share: $2.01
Formula: √(22.5 × EPS × BVPS)
Graham Number
$5.20
38% downside
Base FCF: $28M (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$2.06
76% downside
EPS: $0.60
Target P/E: 43×
Formula: EPS × P/E
P/E Fair Value
$25.80
+205% upside
Institutional Ownership
91.2% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 36.83M | $331.0M | 15.86% | +497.4K | 2026-03-31 |
| STATE STREET CORP | 14.08M | $126.0M | 6.06% | +486.9K | 2026-03-31 |
| Capital Research Global Investors | 11.19M | $100.0M | 4.82% | +4.55M | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.31M | $92.0M | 4.44% | -- | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.87M | $79.0M | 3.82% | -- | 2026-03-31 |
| CITADEL ADVISORS LLC | 6.25M | $56.0M | 2.69% | +4.35M | 2026-03-31 |
| Nuveen, LLC | 6.10M | $54.0M | 2.63% | +171.8K | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 5.82M | $52.0M | 2.51% | -6.8K | 2026-03-31 |
| Caligan Partners LP | 5.06M | $45.0M | 2.18% | +2.04M | 2026-03-31 |
| DIMENSIONAL FUND ADVISORS LP | 5.01M | $45.0M | 2.15% | +169.8K | 2026-03-31 |